Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy.

Discontinuation rates ranged from 1.4% for patients using guselkumab to 5.5% for those treated with infliximab, when the decision was taken by the patients, while ranged between 0.5% for ixekizumab-treated patients and 2.8% for adalimumab-treated when the decision was taken after dermatological consultation. Patients and dermatologists are satisfied using biologics for psoriasis treatment. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. [Extracted from the article]